Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Multiple Myeloma 73Precursor Cell Lymphoblastic Leukemia-Lymphoma 28Burkitt Lymphoma 25Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 11Recurrence 8Immunoglobulin Light-chain Amyloidosis 8Vomiting 7Nausea 7Lymphoma, Mantle-Cell 7Leukemia, Biphenotypic, Acute 7Lymphoma, Large B-Cell, Diffuse 6Lymphoma 6Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasms 5Lymphoma, Non-Hodgkin 5Leukemia, Myeloid, Acute 5Leukemia 5Hodgkin Disease 5Smoldering Multiple Myeloma 4Neoplasms, Plasma Cell 4Neoplasm Metastasis 4Lung Neoplasms 4Breast Neoplasms 4Blast Crisis 4Prostatic Neoplasms 3Plasmacytoma 3Ovarian Neoplasms 3Myelodysplastic Syndromes 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3

Interventions

avapritinib 4midostaurin 3masitinib 2Imatinib Mesylate 2sarilumab 1ripretinib 1obatoclax 1nilotinib 1ibrutinib 1dexamethasone acetate 1dexamethasone 21-phosphate 1denileukin diftitox 1auricularum 1Thalidomide 1Ranitidine 1Ibuprofen 1Everolimus 1Diphenhydramine 1Dexamethasone 1Denosumab 1Dasatinib 1Cladribine 1Calcium Dobesilate 1Brentuximab Vedotin 1Azacitidine 1Acetaminophen 1AK002 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Mastocytosis, Systemic × dexamethasone acetate × Clear all
NCT04681105 2026-01-28

Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

City of Hope Medical Center

Phase 1 Completed
13 enrolled
LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Hairy Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms, Mastocytosis, Systemic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡